Previous Section | Index | Home Page |
26 Mar 2008 : Column 216Wcontinued
Mr. Stephen O'Brien: To ask the Secretary of State for Health how many and what proportion of repeat prescriptions were transferred via the electronic prescriptions service in each month since its inception. [195213]
Mr. Bradshaw: Repeat electronic prescriptions will be transmitted through the electronic prescriptions service with the enablement of Release 2. At present, the system is unable to distinguish practice instigated repeat prescriptions compared to other prescriptions.
Mr. Stephen O'Brien: To ask the Secretary of State for Health (1) how many and what percentage of GP sites were technically live on the Electronic Prescriptions Service system in each month since its inception; and how many and what percentage of GP sites were using the Electronic Prescriptions Service system in each month since its inception; [195257]
(2) how many and what percentage of community pharmacies were technically live on the electronic prescription service system in each month since its inception. [195274]
Mr. Bradshaw: The information requested is shown in the following table.
Technical go livegeneral practitioner | Percentage based on 8,480 sites | Technical go livepharmacy | Percentage based on 10,363 sites | |
Mr. Stephen O'Brien: To ask the Secretary of State for Health how many deployments of the general practitioner system for the electronic prescriptions service have been made, broken down by (a) local service provider and (b) practice. [195263]
Mr. Bradshaw: Existing general practitioner (GP) system suppliers have developed systems that support release one of the electronic prescriptions service (EPS). The EPS has been deployed to 6,663 (79 per cent.) GP practices in England. Through the local service providers, a number of alternative GP systems have been provided to 699 GP practices.
Mr. Stephen O'Brien: To ask the Secretary of State for Health how many and what percentage of dispensing appliance contractors were technically live on the electronic prescriptions service system in each month since its inception; and how many and what percentage of dispensing appliance contractors were using the electronic prescriptions service system in each month since its inception. [195276]
Mr. Bradshaw: There are no dispensing appliance contractors participating in release one of the electronic prescription system.
Mr. Jenkins: To ask the Secretary of State for Health how many prostate screenings there were in (a) Tamworth and (b) Staffordshire in each of the last five years. [193625]
Ann Keen: The national health service, including the South Staffordshire Primary Care Trust, does not operate a prostate cancer screening programme. There is currently insufficient evidence from any country in the world to show that screening would reduce deaths from prostate cancer. The Government are committed to introducing a national screening programme for prostate cancer if and when screening and treatment techniques are sufficiently well developed. The United Kingdom National Screening Committee keeps screening for prostate cancer under review.
The prostate cancer risk management programme was established in 2002 to ensure that men considering a prostate specific antigen (PSA) test are given information concerning the benefits, limitations and risks associated with having a test. Figures on the number of PSA tests taken as a result of the programme are not collected centrally.
Mr. Jenkins: To ask the Secretary of State for Health (1) what percentage of male prisoners eligible for prostate cancer screening have been screened in the last three years; [193634]
(2) what percentage of males eligible for prostate cancer screening have been screened in the last three years in England. [193635]
Ann Keen: The national health service does not operate a prostate cancer screening programme. There is currently insufficient evidence from any country in the world to show that screening would reduce deaths from prostate cancer. The Government are committed to introducing a national screening programme for prostate cancer if and when screening and treatment techniques are sufficiently well developed. The United Kingdom national screening committee keeps screening for prostate cancer under review.
The prostate cancer risk management programme (PCRMP) was established in 2002 to ensure that men considering a prostate specific antigen (PSA) test are given information concerning the benefits, limitations and risks associated with having a test. Figures on the number of PSA tests taken as a result of the programme are not collected centrally.
Mr. Jenkins: To ask the Secretary of State for Health what forecasts he has made for the future requirements for (a) radiographers and (b) radiologists in (i) Tamworth and (ii) the West Midlands. [193628]
Ann Keen: Local national health service organisations are best placed to assess the health needs of their local health community and plan the work force they need.
Next Section | Index | Home Page |